Business Wire

Exscientia Announces Expansion of its Precision Oncology Pipeline


Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a MALT1 protease inhibitor. These compounds have been precision designed to improve the potential for patient benefit and solve complex design issues that may limit the probability of success of other compounds in development. IND-enabling studies are underway and the Company expects to provide an update on clinical development plans leveraging Exscientia's personalised medicine platform in the second half of 2023.

Both molecules were funded through a 2019 collaboration with Celgene, which was acquired by Bristol Myers Squibb, and each molecule met the criteria for which BMS could exercise its option. Bristol Myers Squibb's options to the candidates have now lapsed and Exscientia maintains all worldwide rights to both compounds. In 2021, an agreement was signed to expand the collaboration to include additional programmes in oncology and immunology. These programmes are currently in active development.

“Building off of our success with the CDK7, A2A and PKC-theta programmes, these candidates clearly show how our AI-driven precision design platform can solve challenging target profiles in a more efficient way than traditional drug discovery,” said Professor Andrew Hopkins, D.Phil., founder and Chief Executive Officer of Exscientia. “Both '539 and '565 met the primary nonclinical design goals for potency, selectivity, dosing and safety. In addition, these molecules also have the potential for meaningful patient selection strategies to optimise clinical design. We are excited about the promise these compounds hold in a broad range of haematologic and solid tumours.”

First potent, selective, reversible and brain-penetrant LSD1 inhibitor: EXS74539 ('539)is a differentiated lysine demethylase 1 (LSD1) inhibitor with potential in both haematology and oncology. LSD1 demethylates histones play a critical role in regulating the expression of genes which suppress differentiation and drive the proliferation and survival of a number of tumour types. To date, other LSD1 inhibitors in development have failed to achieve the combination of appropriate pharmacokinetics, good brain penetrance and a reversible mechanism of action. Exscientia's candidate, '539, achieves a design objective of suitable CNS penetration to target brain metastases, which are prevalent in certain cancer subtypes. Additionally, in vivo studies of '539 have shown favourable activity in small cell lung cancer (SCLC) xenograft models, with dose dependent inhibition of tumour growth. Studies have also shown a favourable absorption, distribution, metabolism, and excretion (ADME) profile, with a shorter predicted human half-life than some LSD1 inhibitors currently in clinical trials. No safety concerns have been observed in preclinical studies conducted to date. Exscientia will present data on the discovery and development of '539 at an upcoming scientific conference in the first half of 2023.

Potent and selective MALT1 protease inhibitor with potential safety differentiation: EXS73565 ('565) is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease inhibitor with potential applications in haematology. MALT1 is a protease crucial for activation of the NF-κB pathway which supports the uncontrolled proliferation of malignant T- and B-cells in haematological cancers. Exscientia’s precision design approach was able to optimise the safety profile for agents targeting MALT1 whilst also generating potency and selectivity. Scaffolds of other MALT1 inhibitors in the clinic significantly inhibit UGT1A1, an enzyme involved in the metabolism of bilirubin, often leading to dose-limiting toxicities in the clinic. In vivo studies of '565 have shown anti-tumour activity in mouse models and favourable pharmacokinetics both as monotherapy and in combination with ibrutinib. Toxicology studies have shown that ‘565 has an acceptable therapeutic index, with the ability to maintain high levels of potency, selectivity and safety benchmarks while avoiding meaningful inhibition of UGT1A1, which can lead to hyperbilirubinemia.

“With three existing clinical programmes already in the pipeline, we feel very confident we will meet our goal of four clinical stage compounds in 2024,” said Prof. Hopkins. “Our vision is to change the way drug design, discovery and development is done, as we have shown in our first eight drug candidates. Over the course of 2023, we expect to provide more details on these programmes as well as on our broader internal and partnered pipeline.”

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Visit us at or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, and the timing and progress of, and data reported from, clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding the potential benefit of any of its product candidates or number of clinical stage candidates Exscientia expects to have by 2024. Any statement describing Exscientia’s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that macroeconomic conditions and geopolitical events could have on the Company’s business; the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at, the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Investor Relations:
Sara Sherman

Oliver Stohlmann

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enviva Welcomes REDIII Agreement and Continued Recognition of Biomass as 100% Renewable30.3.2023 23:48:00 CEST | Press release

Enviva Inc. (NYSE: EVA) (“Enviva,” “our,” “we,” or the “Company”) welcomes today’s news that the European Union’s trilogue negotiations concluded with an agreement on the Renewable Energy Directive III (“REDIII” or the “Directive”) and is pleased to hear that woody biomass will continue to be recognized as a renewable energy source in the EU. Although the final text of the agreement has yet to be released publicly, the Company also understands that, encouragingly, the agreement does not impose restrictions on “primary woody biomass,” which will be counted as 100 percent renewable and zero-rated in the EU Emissions Trading System (EU ETS), provided sustainability criteria are fulfilled. As the world’s leading producer of sustainably sourced woody biomass, Enviva is confident that it will be able to meet all updated sustainability criteria, thereby enabling its customers to continue to make an important contribution to achieving global climate goals. Today’s agreement is also expected to

Joe Kiani Wins 2023 Robert L. Wears Patient Safety Leadership Award30.3.2023 22:32:00 CEST | Press release

Joe Kiani, founder of the Patient Safety Movement Foundation (PSMF), has been awarded the 2023 Robert L. Wears Patient Safety Leadership Award in the individual category, along with Dr. Kathryn Kellogg, Vice President for Patient Safety at the MedStar Institute for Quality & Safety. This press release features multimedia. View the full release here: Joe Kiani, Founder of the Patient Safety Movement Foundation and Founder, CEO and Chairman of Masimo (Photo: Business Wire) The award represents recognition for Kiani’s work towards eliminating preventable medical harm and creating a safer healthcare system around the world. For over a decade, his global non-profit, the Patient Safety Movement Foundation has inspired thousands of clinicians around the world to make a public commitment to ZERO harm. The Foundation brought together the best patient safety minds around the world to create Actionable Evidence Based Practices to address t

Abbove Awarded as Best Wealth Technology Outsourcing Solution in Europe30.3.2023 21:00:00 CEST | Press release

Abbove, the wealth planning technology platform was awarded as ‘best technology Outsourcing solution’ at WealthBriefing European Awards 2023. This news coincides with the milestone of 1000 wealth advisors using the platform to guide 30,000 families in achieving their wealth goals. The WealthBriefing Awards have been designed to recognize outstanding organizations grouped by specialism and geography, which the panel of independent judges deemed to have ‘demonstrated innovation and excellence during the last year’. The Belgian wealth-tech is not stopping there, as it now has over 1,000 wealth advisors from private banks and family offices using its technology to place holistic wealth advice at the center of their client relationship. Banking groups such as BNP Paribas Fortis, Quintet Bank or Deutsche Bank in Belgium are trusting Abbove to improve the way they manage, collect and process their client wealth data. Commenting on the firm’s triumph, Guillaume Desclée, CEO, Abbove said: "It’s

Verimatrix Gains EMVCo Security Evaluation Certificate as Software Protection Tool for Mobile Payment Apps30.3.2023 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that its Verimatrix XTD Code Shield toolkit for Android mobile applications received an EMVCo Security Evaluation Certificate as a Software Protection Tool (SPT). The designation demonstrates that Verimatrix’s technology mobile app security tool meets stringent payment security requirements. EMVCo is the global technical body that facilitates the worldwide interoperability and acceptance of secure payment transactions by managing and evolving the EMV® Specifications and related testing processes. Verimatrix gained the Security Evaluation Certificate following the completion of a robust evaluation by Riscure, a leading mobile security lab accredited by EMVCo. As one of Verimatrix’s latest efforts to further streamline the go-to-market process for Android app customers, the EMVCo Security Evaluation Certificate stands as a likely

H.I.G. Capital Acquires Synecore Limited and Meesons Futures Limited to Create the Andwis Group30.3.2023 17:03:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative asset investment firm with $55 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Synecore Limited (“Synecore”) and Meesons Futures Limited (“Meesons”). Synecore and Meesons will join forces with H.I.G.’s existing portfolio companies, CPS and Classic Lifts, to form the Andwis Group (the “Andwis” or the “Andwis Group”), a family of best-in-class technical services providers. The financial terms of the transactions have not been disclosed. Synecore specialises in the delivery and maintenance of HVAC, electrical, air conditioning, and refrigeration services to the hospitality, retail, leisure, and commercial sectors. Synecore, and its network of engineers and suppliers, provides both maintenance and installation services, often supporting site rollout and refurbishment programs. Founded in 1864, Meesons is a physical security and entrance control solutions provider for both crit